International #MedSafetyWeek 2024 campaign week has started
For the ninth time, the international #MedSafetyWeek communications campaign brings together pharmaceutical authorities and organisations and their stakeholders to promote safe pharmacotherapy together.
The 2024 theme emphasises the correct use of medicines to prevent adverse reactions. If any adverse reactions occur, it is important to inform a health care professional about them. Adverse reaction reports are an important part of the safety monitoring of medicines.
The campaign will be visible on social media during the campaign week, 4.–10.11.2024
Fimea participates in the campaign together with 107 other pharmaceutical authorities and organisations from 94 countries.
During the week, Fimea will publish campaign posts on its social media accounts in LinkedIn, X and BlueSky using the hash tag #MedSafetyWeek. Join the campaign by liking and sharing posts to your networks.
The campaign is led by the World Health Organisation’s (WHO) Uppsala Monitoring Centre (UMC). The campaign is supported by WHO and members of the International Coalition of Medicines Regulatory Authorities (ICMRA). More information and promotional materials can be found on the campaign website.
Adverse reaction reports are part of pharmacovigilance
Adverse drug reaction reports are part of pharmacovigilance, which is aimed at identifying, assessing and preventing adverse reactions. Reporting of adverse drug reactions is voluntary and can be done by a health care professional, a consumer or a family member. Adverse reaction reports reflect the observations and opinions of the person making the report and do not mean that there is a confirmed link between the drug and the observed adverse reaction. Conclusions on the benefits and risks of the medicine can only be drawn once all available information has undergone scientific evaluation as part of the continuous safety monitoring of the medicinal product.
Adverse reaction reports are used to detect signals, i.e. signs of possible new adverse reactions. As such, Fimea would like to receive reports especially on adverse reactions that are not mentioned in the medicine’s package leaflet.
Campaign website (Uppsala Monitoring Centre)
Medicines information for the public (Fimea.fi)
Monitoring the safety of medicinal products
Adverse reactions
Submitting a report on an adverse reaction
